AR044362A1 - Derivados de 6,7 dimetoxi isoquinolinas, inhibidores de gfta, compuestos, procedimiento, composicion farmaceutica y usos - Google Patents
Derivados de 6,7 dimetoxi isoquinolinas, inhibidores de gfta, compuestos, procedimiento, composicion farmaceutica y usosInfo
- Publication number
- AR044362A1 AR044362A1 ARP040101684A ARP040101684A AR044362A1 AR 044362 A1 AR044362 A1 AR 044362A1 AR P040101684 A ARP040101684 A AR P040101684A AR P040101684 A ARP040101684 A AR P040101684A AR 044362 A1 AR044362 A1 AR 044362A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- optionally substituted
- aza
- halogen
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se refiere a compuestos de la fórmula general (1), en la que: R1 es 1,4-dioxepanilo o tetrahidropiran-4-ilo; R2 es -N(R)-(CH2)n-heterociclo no aromático de 5 ó 6 eslabones, opcionalmente sustituido por uno o varios sustituyentes elegidos entre alquilo inferior y -NR2 o es -(CH2)n-heterociclo no aromático de 5 ó 6 eslabones, opcionalmente sustituido por -(CH2)n-OH, alquilo inferior, alcoxi inferior o es -(CH2)n-heterociclo aromático de 5 ó 6 eslabones, opcionalmente sustituido por alquilo inferior, alcoxi inferior, halógeno, halógeno-alquilo inferior, -CH2N(R)-(CH2)2OCH3, -N(R)(CH2)2OCH3, -CH2-morfolinilo o -CH2-pirrolidinilo o es (CH2)n-cicloalquilo, opcionalmente sustituido por hidroxi o es -N(R)-cicloalquilo, opcionalmente sustituido por hidroxi o alquilo inferior o es fenilo, opcionalmente sustituido por alcoxi inferior, halógeno, halógeno-alquilo inferior, alquilo inferior, -CH2-pirrolidin-1-ilo, -CH2-morfolinilo, -CH2N(R)(CH2)2OCH3 o -CH2-N(R)C(O)-alquilo inferior o es 1,4-dioxa-8-aza-espiro[4,5]decano o es 2-oxa-5-aza-biciclo[2.2.1]heptano o es 1-oxa-8-aza-espiro[4,5]decano o es -N(R)-7-oxa-biciclo[2.2.1]hept-2-ilo o es 2-aza-biciclo[2.2.2]decano; R es hidrógeno o alquilo inferior; n es el número 0 ó 1; y a sales de adición de ácido farmacéuticamente aceptables de los mismos para el tratamiento de enfermedades en las que interviene el receptor A2A.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03011039 | 2003-05-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR044362A1 true AR044362A1 (es) | 2005-09-07 |
Family
ID=33442729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040101684A AR044362A1 (es) | 2003-05-19 | 2004-05-17 | Derivados de 6,7 dimetoxi isoquinolinas, inhibidores de gfta, compuestos, procedimiento, composicion farmaceutica y usos |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US7371748B2 (es) |
| EP (1) | EP1636223B1 (es) |
| JP (1) | JP4444290B2 (es) |
| KR (1) | KR100859886B1 (es) |
| CN (1) | CN100528871C (es) |
| AR (1) | AR044362A1 (es) |
| AT (1) | ATE389652T1 (es) |
| AU (1) | AU2004251814B2 (es) |
| BR (1) | BRPI0410440A (es) |
| CA (1) | CA2524366C (es) |
| CL (1) | CL2004001067A1 (es) |
| CO (1) | CO5630031A2 (es) |
| DE (1) | DE602004012555T2 (es) |
| DK (1) | DK1636223T3 (es) |
| ES (1) | ES2301991T3 (es) |
| HK (1) | HK1092469A1 (es) |
| HR (1) | HRP20080207T3 (es) |
| IL (1) | IL171686A (es) |
| MX (1) | MXPA05012360A (es) |
| NO (1) | NO20055150L (es) |
| NZ (1) | NZ543074A (es) |
| PL (1) | PL1636223T3 (es) |
| PT (1) | PT1636223E (es) |
| RU (1) | RU2351597C2 (es) |
| SI (1) | SI1636223T1 (es) |
| TW (1) | TW200505882A (es) |
| WO (1) | WO2005000842A1 (es) |
| ZA (1) | ZA200509294B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008052930A2 (en) * | 2006-11-03 | 2008-05-08 | F. Hoffmann-La Roche Ag | Preparation of 4-alk0xy-7- (tetrahydropyran-4-yl) benzothiazol-2-amine derivatives |
| FI3661941T3 (fi) | 2017-08-01 | 2023-03-23 | Merck Patent Gmbh | Tiatsolopyridiinijohdannaisia adenosiinireseptoriantagonisteina |
| TW201920123A (zh) * | 2017-08-21 | 2019-06-01 | 德商馬克專利公司 | 作為腺苷受體拮抗劑之喹㗁啉衍生物 |
| TWI791593B (zh) * | 2017-08-21 | 2023-02-11 | 德商馬克專利公司 | 做為腺苷受體拮抗劑之苯并咪唑衍生物 |
| WO2019141096A1 (zh) * | 2018-01-19 | 2019-07-25 | 四川科伦博泰生物医药股份有限公司 | 取代脲类化合物及其制备方法和用途 |
| WO2020083878A1 (en) | 2018-10-25 | 2020-04-30 | Merck Patent Gmbh | 5-azaindazole derivatives as adenosine receptor antagonists |
| US20210361669A1 (en) | 2018-10-25 | 2021-11-25 | Merck Patent Gmbh | 5-azaindazole derivatives as adenosine receptor antagonists |
| AR117844A1 (es) * | 2019-01-22 | 2021-09-01 | Merck Patent Gmbh | Derivados de tiazolopiridina como antagonistas del receptor de adenosina |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1797878A3 (en) * | 2000-06-21 | 2010-01-20 | F. Hoffmann-La Roche AG | Benzothiazole derivatives |
| AU2002352045B2 (en) * | 2001-11-27 | 2006-08-17 | F. Hoffmann-La Roche Ag | 7-morpholin-4YL-benzothiazole amide derivatives |
| US6727247B2 (en) * | 2001-12-10 | 2004-04-27 | Hoffman-La Roche Inc. | Substituted benzothiazole amide derivatives |
| US6734179B2 (en) * | 2001-12-12 | 2004-05-11 | Hoffmann-La Roche Inc. | Benzothiazoles |
| KR100699615B1 (ko) * | 2003-01-13 | 2007-03-23 | 에프. 호프만-라 로슈 아게 | 벤족사졸 유도체 및 아데노신 수용체 리간드로서의 이들의용도 |
-
2004
- 2004-05-14 PT PT04732950T patent/PT1636223E/pt unknown
- 2004-05-14 MX MXPA05012360A patent/MXPA05012360A/es active IP Right Grant
- 2004-05-14 CA CA2524366A patent/CA2524366C/en not_active Expired - Fee Related
- 2004-05-14 WO PCT/EP2004/005178 patent/WO2005000842A1/en active IP Right Grant
- 2004-05-14 RU RU2005139527/04A patent/RU2351597C2/ru not_active IP Right Cessation
- 2004-05-14 KR KR1020057021945A patent/KR100859886B1/ko active IP Right Grant
- 2004-05-14 SI SI200430668T patent/SI1636223T1/sl unknown
- 2004-05-14 JP JP2006529816A patent/JP4444290B2/ja not_active Expired - Fee Related
- 2004-05-14 CN CNB2004800135624A patent/CN100528871C/zh not_active Expired - Fee Related
- 2004-05-14 DK DK04732950T patent/DK1636223T3/da active
- 2004-05-14 EP EP04732950A patent/EP1636223B1/en not_active Expired - Lifetime
- 2004-05-14 PL PL04732950T patent/PL1636223T3/pl unknown
- 2004-05-14 AT AT04732950T patent/ATE389652T1/de active
- 2004-05-14 NZ NZ543074A patent/NZ543074A/en unknown
- 2004-05-14 AU AU2004251814A patent/AU2004251814B2/en not_active Ceased
- 2004-05-14 ES ES04732950T patent/ES2301991T3/es not_active Expired - Lifetime
- 2004-05-14 DE DE602004012555T patent/DE602004012555T2/de not_active Expired - Lifetime
- 2004-05-14 TW TW093113590A patent/TW200505882A/zh unknown
- 2004-05-14 BR BRPI0410440-4A patent/BRPI0410440A/pt not_active Application Discontinuation
- 2004-05-17 CL CL200401067A patent/CL2004001067A1/es unknown
- 2004-05-17 US US10/847,558 patent/US7371748B2/en not_active Expired - Fee Related
- 2004-05-17 AR ARP040101684A patent/AR044362A1/es not_active Application Discontinuation
-
2005
- 2005-10-31 IL IL171686A patent/IL171686A/en active IP Right Grant
- 2005-11-03 NO NO20055150A patent/NO20055150L/no not_active Application Discontinuation
- 2005-11-16 ZA ZA200509294A patent/ZA200509294B/en unknown
- 2005-11-16 CO CO05116289A patent/CO5630031A2/es not_active Application Discontinuation
-
2006
- 2006-11-29 HK HK06113066.6A patent/HK1092469A1/xx not_active IP Right Cessation
-
2008
- 2008-05-08 HR HR20080207T patent/HRP20080207T3/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602006006850D1 (de) | Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate | |
| AR046711A1 (es) | 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones | |
| AR052887A1 (es) | Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR067662A1 (es) | Derivados de benzo[d]isoxazol-3-il-piperidina, medicamentos que los contienen y usos terapeuticos para enfermedades asociadas al sistema nervioso. | |
| AR054786A1 (es) | (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1 | |
| AR051294A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
| UY28578A1 (es) | Derivados de amida | |
| AR054799A1 (es) | Derivados de oxindol | |
| CR7496A (es) | Piridinoilpiperidinas como agonistas de 5- ht1f | |
| AR059016A4 (es) | Derivados de aril-isoxazol-4-il-imidazo[1,2-a]piridina, metodo de preparacion, medicamentos que los contienen y usos en el tratamiento de trastornos cognitivos. | |
| PE20011371A1 (es) | Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5 | |
| AR056860A1 (es) | Derivados de triazol inhibidores de receptores de quinasa tgf-beta1, composiciones farmaceuticas que los contienen y usos para el tratamiento de tumores | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| AR066972A1 (es) | Derivados azapeptidicos | |
| PE20060336A1 (es) | Compuestos derivados de 1-amino-ftalazina como moduladores de mch1 | |
| NO20055977L (no) | Nye benzimidazolderivater | |
| AR053435A1 (es) | Derivados de 5-amminoindol, un metodo para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un madicamento para el tratamiento de enfermedades asociadas a la modulacion de receptores h3. | |
| PE20030718A1 (es) | Lactamas como antagonistas de taquiquininas | |
| AR042362A1 (es) | Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen | |
| ECSP088257A (es) | Derivados de amida | |
| AR057197A1 (es) | Derivados de 1, 1-dioxo-tiomorfolinil-indolil-metanona | |
| PE20061196A1 (es) | Tetrahidropiridoazepin-8-onas y compuestos relacionados para el tratamiento de la esquizofrenia | |
| AR044362A1 (es) | Derivados de 6,7 dimetoxi isoquinolinas, inhibidores de gfta, compuestos, procedimiento, composicion farmaceutica y usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |